Nanocarriers market seen topping $23B by 2030

The Business Research Company says the global nanocarriers market is on track to exceed $23 billion by 2030, driven by targeted drug delivery, mRNA therapies and broader nanomedicine adoption. North America and the U.S. are forecast to lead the market, while polymeric nanocarriers remain the biggest product segment.

Why it matters: - Nanocarriers are moving from a niche technology to a core part of drug delivery and nanomedicine. - The market’s projected growth points to rising demand for precision oncology, RNA therapeutics and controlled-release treatments. - The segment is expected to capture a larger share of pharmaceutical spending as advanced delivery systems become more widely used.

What happened: - The Business Research Company released its Nanocarriers Global Market Report 2026 with forecasts through 2035. - The report says the nanocarriers market will exceed $23 billion by 2030. - The market is forecast to grow at a 16% compound annual growth rate through 2030. - North America is projected to lead the market by 2030 with a value of $10.5 billion. - The U.S. is expected to be the largest country market in 2030 at $9.6 billion. - Polymeric nanocarriers are forecast to be the largest type segment, reaching about $12 billion and 52% market share by 2030.

The details: - The report places the nanocarriers market at roughly 40% of the broader nanomedicine market by 2030. - The nanomedicine market is projected to reach about $782 billion in 2030. - The overall pharmaceuticals market is expected to reach $2,496 billion in 2030, putting nanocarriers at nearly 1% of the total. - North America’s market is forecast to rise from $5.0 billion in 2025 to $10.5 billion in 2030. - The U.S. market is forecast to grow from $4.6 billion in 2025 to $9.6 billion in 2030. - The report ties North American growth to commercialization of nanomedicine-based drug delivery, broader use of targeted therapies in oncology and chronic disease, and a strong research base. - The U.S. outlook is supported by precision oncology adoption, lipid-based and polymeric nanocarrier use, investment in biologics and complex formulations, and GMP-grade manufacturing buildout. - The market covers drug delivery, diagnostics, vaccines, gene therapy and other medical uses. - End users include pharmaceutical and biotechnology companies, hospitals and clinics, research institutes and other healthcare providers. - The report says polymeric nanocarriers are growing on advances in polymer engineering, stimuli-responsive delivery systems and applications in gene therapy and RNA-based treatments. - The combined polymeric, lipid-based, inorganic and other nanocarrier segments are expected to exceed $12 billion by 2030. - The report estimates 2025-to-2030 growth of $6 billion for polymeric nanocarriers, $3 billion for lipid-based nanocarriers, $2 billion for inorganic nanocarriers and $1 billion for other types. - Pfizer Inc. led global nanocarriers sales in 2025 with a 4% market share. - The top ten companies accounted for 23% of market revenue in 2025, indicating a moderately fragmented market. - Major companies named in the report include Moderna, BioNTech, AstraZeneca, Roche, Johnson & Johnson, Sanofi, Merck & Co., Amgen, Novartis, Evonik and Bristol-Myers Squibb. - The report names Thermo Fisher Scientific, Merck KGaA, Evonik, BASF and Dow among raw material suppliers. - Distributors listed include McKesson, Cardinal Health, Cencora, Owens & Minor, Medipal Holdings and Walgreens Boots Alliance Distribution.

Between the lines: - The forecast reflects a market where delivery technology is becoming as important as the drug payload itself. - Lipid nanoparticle success in mRNA vaccines appears to be broadening interest in RNA delivery and gene therapy platforms. - Competitive pressure is shifting toward scalable manufacturing, regulatory readiness and multifunctional platforms rather than simple formulation alone. - The report’s company rankings suggest no single player dominates the category, leaving room for specialized developers and partnership-driven growth. - Oncotelic Therapeutics subsidiary Sapu Nano unveiled the Deciparticle nanomedicine platform in March 2026, highlighting industry interest in sub-20 nm systems for intravenous delivery of hydrophobic oncology drugs.

What's next: - The report expects continued adoption of nanocarriers in oncology, precision medicine and nucleic acid delivery through 2030. - Companies are likely to keep investing in functionalized nanoparticles, scalable production and AI-assisted drug design. - Further growth will depend on clinical translation, regulatory approvals and broader commercial manufacturing capacity.

The bottom line: - Nanocarriers are becoming a major enabling technology for next-generation medicines, with the strongest growth concentrated in North America, the U.S. and polymer-based delivery systems.